Russell Investments Group Ltd. Grows Stock Position in Glaukos Corporation $GKOS

Key Points

• Russell Investments Group Ltd. increased its stake in Glaukos Corporation by 174.9%, now owning approximately 0.07% of the company, valued at about $3.8 million.
• Glaukos Corporation has received mixed analyst ratings, with target prices ranging from $72.00 to $134.00, and a consensus rating of "Moderate Buy".
• The company reported a revenue increase of 29.7% year-over-year, despite a reported EPS of ($0.24), which exceeded expectations.

Russell Investments Group Ltd. boosted its holdings in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 174.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 38,393 shares of the medical instruments supplier's stock after buying an additional 24,428 shares during the period. Russell Investments Group Ltd. owned approximately 0.07% of Glaukos worth $3,779,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in GKOS. Dimensional Fund Advisors LP boosted its stake in Glaukos by 9.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 312,314 shares of the medical instruments supplier's stock valued at $46,828,000 after buying an additional 26,540 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Glaukos during the fourth quarter valued at $182,000. MetLife Investment Management LLC boosted its stake in Glaukos by 5.9% during the fourth quarter. MetLife Investment Management LLC now owns 29,561 shares of the medical instruments supplier's stock valued at $4,432,000 after buying an additional 1,659 shares during the period. State of Tennessee Department of Treasury boosted its stake in Glaukos by 5.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 24,021 shares of the medical instruments supplier's stock valued at $3,602,000 after buying an additional 1,328 shares during the period. Finally, Stifel Financial Corp boosted its stake in Glaukos by 2.6% during the fourth quarter. Stifel Financial Corp now owns 4,341 shares of the medical instruments supplier's stock valued at $651,000 after buying an additional 111 shares during the period. Institutional investors own 99.04% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on GKOS. Truist Financial reissued a "buy" rating and set a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. Morgan Stanley cut their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Zacks Research cut Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. Wells Fargo & Company boosted their target price on Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Finally, Stephens dropped their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $127.42.

Glaukos Trading Up 1.5%

Shares of GKOS traded up $1.42 during trading hours on Thursday, hitting $96.54. The company had a trading volume of 549,249 shares, compared to its average volume of 1,060,269. The firm has a market cap of $5.54 billion, a P/E ratio of -58.51 and a beta of 0.78. The stock's 50 day moving average price is $95.71 and its 200 day moving average price is $99.82. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 52-week low of $77.10 and a 52-week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. The firm had revenue of $124.12 million for the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The company's quarterly revenue was up 29.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. On average, research analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.